Quartz on MSN1d
A new stronger Ozempic is coming. Here's what to know
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Novo's new obesity drug, Wegovy in race to becoming top selling franchise
Novo Nordisk A/S’s appetite-blocking shot semaglutide ... cagrilintide forms a hybrid the company calls CagriSema.
Bloomberg L.P. on MSN9d
Novo Nordisk Shares Seen Outpacing Lilly’s After Summer Stumble
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity ...
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Big Pharma’s Obesity Bonanza Faces New Tests
It isn’t that Wall Street doubts the massive opportunity to treat hundreds of millions of people with obesity worldwide; ...